Cluster Purchases by Insiders of new IPO Scribe Therapeutics
Insider Weekends
Insider buying was once again muted last week due to earnings-related quiet period restrictions at most companies. The only reason aggregate insider buying spiked, was on account of $56.34 million worth of insider purchases tied to a biotech IPO. Once you remove those purchases, insider buying dropped to just $11.71 million last week. I was conflicted b…
Keep reading with a 7-day free trial
Subscribe to The Special Situation Report to keep reading this post and get 7 days of free access to the full post archives.